Insider Buying: Fennec Pharmaceuticals Inc. (TSE:FRX) Director Purchases C$96,840.00 in Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov purchased 25,000 shares of the stock in a transaction dated Friday, December 20th. The shares were bought at an average cost of C$3.87 per share, for a total transaction of C$96,840.00.

Rostislav Christov Raykov also recently made the following trade(s):

• On Thursday, December 5th, Rostislav Christov Raykov acquired 796 shares of Fennec Pharmaceuticals stock. The shares were bought at an average cost of C$8.52 per share, for a total transaction of C$6,779.05.
• On Wednesday, October 2nd, Rostislav Christov Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$6.67, for a total transaction of C$16,212.34.

Fennec Pharmaceuticals Trading Up 0.2 %

Shares of FRX stock opened at C$8.93 on Thursday. The stock has a market cap of C$244.32 million, a P/E ratio of 89.30 and a beta of 0.25. The company has a quick ratio of 10.17, a current ratio of 8.02 and a debt-to-equity ratio of 1,040.68. Fennec Pharmaceuticals Inc. has a fifty-two week low of C$5.65 and a fifty-two week high of C$15.43. The business has a fifty day simple moving average of C$7.25 and a 200-day simple moving average of C$7.67.

Analyst Upgrades and Downgrades

Separately, Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 18th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.